FDA Response to Adverse Event Issues - Sponsored Whitepaper

In the wake of the recent spate of drug withdrawals and other drug safety issues, there have been renewed calls to reform and enhance the U.S. approach to monitoring safety issues in marketed products. These calls have come from many quarters, and a variety of initiatives have been the result.